Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials

Multiple Sclerosis

Volumn 6, Issue 2, 2000, Pages 99-104

  Tan, I L ^a   Lycklama A Nijeholt G J ^a   Polman, C H ^a   Ader H J ^b   Barkhof, F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Linomide; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

ROQUINIMEX;

ADULT; ALLERGIC ENCEPHALITIS; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REBOUND; RECURRENCE RISK;

EID: 0034003613     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245850000600208     Document Type: Article

References (21)

1. The IFNB. (1995) Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis. Neurology 45: 1277-1285.
2. Stone LA et al. (1997) Characterization of MRI response to the treatment with interferon beta-1b. Neurology 49: 862-869.
3. Johnson KP et al. (1995) Copolymer 1 reduces relapse rates and improves disability in relapsing remitting multiple sclerosis. Neurology 45: 1268-1276.
4. Mancardi GL et al. (1998) Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multi-ple sclerosis. Neurology 50: 1127-1133.
5. Bastianello S et al. (1994) A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sci 21: 266-270.
6. Tian WZ et al. (1998) Linomide (Roquinimex) affects the balance between pro- and anti-inflammatory cytokines in vitro in multiple sclerosis. Acta Neurol Scand 98: 94-101.
7. Karussis D et al. (1993) Successful treatment of chronic-relapsing experimental autoimmune encephalomyelitis by the synthetic immunomodulator Linomide (quinoline-3-carboxamide). Proc Natl Acad Sci 90: 6400-6404.
8. Karussis D et al. (1993) Inhibition of acute experimental autoimmune encephalomyelitis by the synthetic immunomodulator Linomide. Ann Neurol 34: 654-660.
9. Diab A et al. (1998) Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammator versus anti-inflammatory cytokines. J Neuroimmunol 85: 146-154.
10. Miller DH et al. (1996) Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurology 39: 6-16.
11. Barkhof F et al. (1997) Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. J Neurol 244: 76-84.
12. Miller DH, Barkhof F, Nauta JJP. (1993) Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 116: 1077-1094.
13. Karussis DM et al. (1996) Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 47: 341-346.
14. Andersen O et al. (1996) Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 47: 895-900.
15. Kurtzke JF. (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 83: 1444-1452.
16. Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurology 13: 1227-1231.
17. OffenbacherH et al. (1993) Assessment of MRI criteria for a diagnosis of MS. Neurology 43: 905-909.
18. Paty DW et al. (1988) MRI in the diagnosis of MS: A prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 38: 180-185.
19. Filippi M et al. (1997) Sensitivity of delayed gadolinium-enhanced MRI in multiple sclerosis. Acta Neurol Scand 95: 331-334.
20. Barkhof F et al. (1997) Improving interobserver variation in reporting gadolinium-enhanced MS lesions. Neurology 49: 1682-1688.
21. Xiao BG et al. (1998) Linomide-mediated protection of oligodendrocytes is associated with inhibition of nitric oxide production and il-1-beta expression in Lewis rat glial cells. Neurosci Lett 249: 17-20.